The role of pixantrone in the treatment of on-Hodgkin's lymphoma

Expert Opinion on Investigational Drugs

Volumn 14, Issue 8, 2005, Pages 1055-1061

  Borchmann, Peter ^a   Schnell, Roland ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Anthracycline; BBR 2778; non Hodgkin's lymphoma; Pixantrone; Topoisomerase II inhibitor

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GYRASE INHIBITOR; METHYLPREDNISOLONE; MITOXANTRONE; PIXANTRONE; PREDNISONE; PROCARBAZINE; RITUXIMAB; UNCLASSIFIED DRUG; VINCRISTINE;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CYTOTOXICITY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG URINE LEVEL; HUMAN; LEUKEMIA; LYMPHOCYTOPENIA; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; SKIN DISCOLORATION; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA TOPOISOMERASES, TYPE II; HUMANS; ISOQUINOLINES; LYMPHOMA, NON-HODGKIN;

EID: 23644436045     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.8.1055     Document Type: Review

References (44)

1. ABRAHAM R, BASSER RL, GREEN MD: A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy. Drug Saf. (1996) 15:406-429.
2. BASSER RL, GREEN MD: Strategies for prevention of anthracycline cardiotoxicity. Cancer Treat. Rev. (1993) 19:57-77.
3. SINGAL PK, ILISKOVIC N: Current Concepts: Doxorubicin Induced Cardiomyopathie. N. Engl. J. Med. (1998) 339:900-905.
4. DENNY WA, WAKELIN LP: Kinetics of the binding of mitoxantrone, ametantrone and analogues to DNA: relationship with binding mode and anti-tumour activity. Anticancer Drug Des. (1990) 5:189-200.
5. LOWN JW, MORGAN AR, YEN SF, WANG YH, WILSON WD: Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids. Biochemistry (1985) 24:4028-4035.
6. DE ISABELLA P, PALUMBO M, SISSI C et al.: Physicochemical properties, cytotoxic activity and topoisomerase II inhibition of 2,3-diaza-anthracenediones. Biochem Pharmacol. (1997) 53:161-169.
7. HAZLEHURST LA, ALSINA M, HACKER MP: Investigations on the Mechanisms of Resistance to Pixantrone in Tumor Cells. Blood (2004) 104:3402.
8. BERTAZZOLI C, BELLINI O, MAGRINI U, TOSANA MG: Quantitative experimental evaluation of adriamycin cardiotoxicity in the mouse. Cancer Treat Rep. (1979) 63:1877-1883.
9. BEGGIOLIN G, CRIPPA L, MENTA E et al.: Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori (2001) 87:407-416.
10. FISHER SG, FISHER RI: The epidemiology of non-Hodgkin's lymphoma. Oncogene (2004) 23:6524-6534.
11. COIFFIER B, LEPAGE E, BRIERE J et al.: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N. Engl J. Med. (2002) 346:235-242.
12. HIDDEMANN W, FORSTPOINTNER R, KNEBA M et al.: The Addition of Rituximab to Combination Chemotherapy with CHOP Has a Long Lasting Impact on Subsequent Treatment in Remission in Follicular Lymhoma but Not in Mantle Cell Lymphoma: Results of Two Prospective Randomized Studies of the German Low Grade Lymphoma Study Group (GLSG). Blood (2004) 104:161.
13. MARCUS R, IMRIE K, BELCH A et al.: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood (2005) 105:1417-1423.
14. PFREUNDSCHUH M, TRUMPER L, KLOESS M et al.: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood (2004) 104:634-641.
15. PFREUNDSCHUH M, TRUMPER L, KLOESS M et al.: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood (2004) 104:626-633.
16. MARTINO R, PEREA G, CABALLERO MD et al.: Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. Haematologica (2002) 87:822-827.
17. TSAVARIS N, KOSMAS C, VADIAKA M et al.: Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. Anticancer Res. (2002) 22:1845-1848.
18. AVILES A, NERI N, CASTANEDA C, TALAVERA A, HUERTA-GUZMAN J, GONZALEZ M: Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma. Med. Oncol. (2002) 19:55-58.
19. McBRIDE NC, CAVENAGH JD, WARD MC et al.: Liposomal daunorubicin (DaunoXome) in combination with cyclophosphamide, vincristine and prednisolone (COP-X) as salvage therapy in poor-prognosis non-Hodgkin's lymphoma. Leuk. Lymphoma (2001) 42:89-98.
20. TULPULE A, RARICK MU, KOLITZ J et al.: Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. Ann. Oncol. (2001) 12:457-462.
21. FLINN IW, GOODMAN SN, POST L et al.: A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL. Ann. Oncol. (2000) 11:691-695.
22. RICHARDSON DS, KELSEY SM, JOHNSON SA, TIGHE M, CAVENAGH JD, NEWLAND AC: Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma. Invest. New Drugs (1997) 15:247-253.
23. HAGEMEISTER F, CABANILLAS F, COLEMAN M, GREGORY SA, ZINZANI PL: The role of mitoxantrone in the treatment of indolent lymphomas. Oncologist (2005) 10:150-159.
24. RODRIGUEZ MA, CABANILLAS FC, VELASQUEZ W et al.: Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J. Clin. Oncol. (1995) 13:1734-1741.
25. KRAPCHO AP, PETRY ME, GETAHUN Z et al.: 6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinolin e-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations. J. Med. Chem. (1994) 37:828-837.
26. ZWELLING LA, MAYES J, ALTSCHULER E, SATITPUNWAYCHA P, TRITTON TR, HACKER MP: Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II. Biochem. Pharmacol. (1993) 46:265-271.
27. SISSI C, MORO S, ZAGOTTO G et al.: Binding of bis-substituted 2-aza-anthracenedione regioisomers to DNA: effects of the relative positioning of the side chains. Anticancer Drug Des. (1999) 14:265-274.
28. ANDOH T, ISHIDA R: Catalytic inhibitors of DNA topoisomerase II. Biochim. Biophys. Acta (1998) 1400:155-171.
29. DE ISABELLA P, PALUMBO M, SISSI C et al.: Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. Mol. Pharmacol. (1995) 48:30-38.
30. HAZLEHURST LA, KRAPCHO AP, HACKER MP: Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: aza-anthracenediones. Cancer Lett. (1995) 91:115-124.
31. CAVALETTI E, CRIPPA L, MELONI E, BELLINI O, TOGNELLA S, GIULINI FC: BBR2778, a novel aza-anthracenedione: preclinical toxicological evaluation. Proc. Ann. Meet. Assoc. Cancer Res. (1993) 34:2227.
32. FAIVRE S, RAYMOND E, BOIGE V et al.: A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin. Cancer Res. (2001) 7:43-50.
33. BORCHMANN P, KNIPPERTZ R, SCHNELL R et al.: Pharmacokinetics and clinical results of the new aza-anthracenedione BBR2778 in patients with advanced non-Hodgkin lymphomas. Blood (1999) 102:4364.
34. LEVINE AM, FAYAD L, TULPULE A et al.: Results of a Phase I/II Trial with BBR-2778 (Pixantrone), Methylprednisolone, Cisplatin, and Cytosine Arabinoside (BSHAP) in Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma (NHL). Blood (2003) 102:2364.
35. HERBRECHT R, MORSCHHAUSER F, HESS G et al.: Preliminary Phase II Study results of BBR2778 in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma. Blood (2004) 104:2489.
36. CAVALETTI G, CAVALETTI E, CRIPPA L et al.: Pixantrone (BBR2778) reduces the severity of experimental allergic encephalomyelitis. J. Neuroimmunol. (2004) 151:55-65.
37. DAWSON LK, JODRELL DI, BOWMAN A et al.: A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur. J. Cancer (2000) 36:2353-2359.
38. BORCHMANN P, SCHNELL R, KNIPPERTZ R et al.: Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann. Oncol. (2001) 12:661-667.
39. BORCHMANN P, MORSCHHAUSER F, PARRY A et al.: Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematologica (2003) 88:888-894.
40. FAYAD L, LIEBMANN J, MODIANO M et al.: Preliminary Results of a Phase I/II Trial of BBR-2778 (Pixantrone) in Combination with Fludarabine, Dexamethasone, and Rituximab (FPD-R) in the Treatment of Patients with Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (NHL). Blood (2004) 104:1324.
41. MARTINO R, PEREA G, CABALLERO MD et al.: Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective phase II study. Haematologica (2002) 87:822-827.
42. TSAVARIS N, KOSMAS C, VADIAKA M et al.: Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin's lymphoma. Anticancer Res. (2002) 22:1845-1848.
43. AVILES A, NERI N, CASTANEDA C, TALAVERA A, HUERTA-GUZMAN J, GONZALEZ M: Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma. Med. Oncol. (2002) 19:55-58.
44. KUMAR S, LACY MQ, DISPENZIERI A et al.: Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant (2004) 34:485-490.